Altimmune, Inc. - Common Stock (NQ:ALT)

4.360 -0.100 (-2.24%)

Streaming Delayed Price Updated: 12:47 PM EST, Feb 27, 2026 Add to My Watchlist

Price and Volume

Volume	641,011
Open	4.400
Bid (Size)	4.350 (4,300)
Ask (Size)	4.360 (900)
Prev. Close	4.460
Today's Range	4.320 - 4.470
52wk Range	2.900 - 7.730
Shares Outstanding	95,598,665
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Forget Altimmune: This Proven Obesity‑Drug Giant Is the Better Weight‑Loss Play ↗

February 26, 2026

The maker of Wegovy hasn't said its last words just yet.

Via The Motley Fool

Nasdaq, S&P 500 Futures Edge Higher Ahead Of Fed Decision, Mag 7 Earnings Kick Off: Why NVDA, ASML, ALT, AI, UUU Are On Traders' Radar Today ↗

January 28, 2026

Retail sentiment on major ETFs such as SPY and QQQ turned ‘extremely bearish’ on Stocktwits.

Via Stocktwits

Performance

YTD	+24.2%	+24.2%
1 Month	-29.4%	-29.4%
3 Month	-17.1%	-17.1%
6 Month	+17.5%	+17.5%
1 Year	-26.6%	-26.6%

More News

ALT Stock Surges Toward Sixth Straight Day Of Gains: Retail Bets A Buyout Is On The Horizon ↗

January 27, 2026

Via Stocktwits

Nasdaq, S&P 500 Futures Subdued Ahead Of PMI Data: Why INTC, TSLA, NFLX, VST, MOVE Are On Traders' Radar Today ↗

January 23, 2026

Via Stocktwits

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

ALT Stock Rallies 4% — What Does Retail Think? ↗

January 22, 2026

Via Stocktwits

Why Are Investors Looking At Altimmune Stock? ↗

January 05, 2026

Via Benzinga

Altimmune Receives FDA’s Breakthrough Therapy Designation For Its Liver Disease Drug ↗

January 05, 2026

Via Stocktwits

Altimmune Stock Soars Over 10% Premarket On Positive Mid-Stage Data For Liver Disease Treatment Drug ↗

December 19, 2025

Via Stocktwits

Altimmune Stock Attracts Strong Retail Buzz As Investors Count Down To 48-Week Data For Its Fatty Liver Treatment ↗

November 17, 2025

Via Stocktwits

Important Notice to Long-Term Shareholders of Altimmune, Inc. (NASDAQ: ALT); Five Below, Inc. (NASDAQ: FIVE); Flywire Corporation (NASDAQ: FLYW); and Hertz Global Holdings, Inc. (NASDAQ: HTZ): Grabar Law Office is Investigating Claims on Your Behalf

October 16, 2025

From Grabar Law Office

Via GlobeNewswire

Altimmune Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) ↗

October 10, 2025

Via Benzinga

ALTIMMUNE ALERT: Bragar Eagel & Squire, P.C. is Investigating Altimmune, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

October 08, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

October 06, 2025

From Faruqi & Faruqi, LLP

Via Business Wire

ALTIMMUNE FINAL DEADLINE REMINDER: Bragar Eagel & Squire, P.C. Urges Investors to Contact the Firm Regarding the October 6th Deadline

October 06, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

Levi & Korsinsky Reminds Altimmune Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 6, 2025 - ALT

October 06, 2025

Via NewMediaWire

Levi & Korsinsky Reminds Altimmune Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 6, 2025 - ALT

October 06, 2025

Via TheNewswire.com

ALT INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

October 05, 2025

From Faruqi & Faruqi LLP

Via GlobeNewswire

ALTIMMUNE CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. Reminds Investors of October 6th Deadline and Urges Investors to Contact the Firm

October 03, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

Altimmune, Inc. Class Action: Levi & Korsinsky Reminds Altimmune Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 6, 2025 - ALT

October 03, 2025

Via NewMediaWire

Altimmune, Inc. Class Action: Levi & Korsinsky Reminds Altimmune Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 6, 2025 - ALT

October 03, 2025

Via TheNewswire.com

Contact Levi & Korsinsky by October 6, 2025 Deadline to Join Class Action Against Altimmune, Inc. (ALT)

October 01, 2025

Via NewMediaWire

Contact Levi & Korsinsky by October 6, 2025 Deadline to Join Class Action Against Altimmune, Inc. (ALT)

October 01, 2025

Via TheNewswire.com

ALT DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 6 Deadline in Securities Class Action - ALT

September 30, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

Altimmune, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – ALT

September 30, 2025

From DJS Law Group

Via Business Wire

Frequently Asked Questions

Is Altimmune, Inc. - Common Stock publicly traded?

Yes, Altimmune, Inc. - Common Stock is publicly traded.

What exchange does Altimmune, Inc. - Common Stock trade on?

Altimmune, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Altimmune, Inc. - Common Stock?

The ticker symbol for Altimmune, Inc. - Common Stock is ALT on the Nasdaq Stock Market

What is the current price of Altimmune, Inc. - Common Stock?

The current price of Altimmune, Inc. - Common Stock is 4.360

When was Altimmune, Inc. - Common Stock last traded?

The last trade of Altimmune, Inc. - Common Stock was at 02/27/26 12:47 PM ET

What is the market capitalization of Altimmune, Inc. - Common Stock?

The market capitalization of Altimmune, Inc. - Common Stock is 416.81M

How many shares of Altimmune, Inc. - Common Stock are outstanding?

Altimmune, Inc. - Common Stock has 417M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.